GLMD
Galmed Pharmaceuticals Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$3.88
−1.02%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -37.7%
- EBIT
- -41.7%
- EPS
- +83.6%
- Free cash flow
- -56.2%
- Operating cash flow
- -56.2%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +54.3%
Three-year CAGR
- Revenue
- —
- EBITDA
- -39.0%
- EBIT
- -35.6%
- Net income
- -37.1%
- EPS
- +70.4%
- Free cash flow
- -7.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026